Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial.

A secondary analysis of NCT04255433. The report of the trial’s main result is not on the map, and the numbers here are shown and do not vote.

What the trial testedas reported · 13,165 people · 2026

Not counted

−16%−21% to −10%

24 in 100 instead of 27

Bigger than 4 in 10 on the map

As reported

HR 0.84, 95% CI 0.79–0.90

the abstract, start to end

… patients (27.4%; hazard ratio [HR], 0.84; 95% CI, 0.79-0.90; P < .001).

← favours treatmentfavours comparator →

could be chance

Kidney outcomes

HR 0.840.79–0.90

GLP-1 receptor agonistsGIP/GLP-1 & amylin agonistsKidney outcomes

1 / 3

2026

this papercites it